Management of Parkinson's disease: Defining the role of entacapone

Disease Management and Health Outcomes

Volumn 10, Issue 10, 2002, Pages 643-659

  Ibbotson, Tim ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BENSERAZIDE; BENZATROPINE; BROMOCRIPTINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; AGED; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COST CONTROL; DIARRHEA; DOSE RESPONSE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; DYSKINESIA; FEMALE; HALLUCINATION; HEALTH CARE COST; HUMAN; HYPERKINESIA; MALE; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NEUROSURGERY; PARKINSON DISEASE; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW;

EID: 0036399672     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200210100-00005     Document Type: Review

References (74)

1. Holm KJ. Spencer CM. Entacapone: a review of its use in Parkinson's disease. Drugs 1999; 58: 159-77
2. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-9
3. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. Neurology 2001; 56 (Suppl. 5): SI-S88
4. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42
5. Hauser RA, Zesiewicz TA. Management of early Parkinson's disease. Med Clin North Am 1999; 83: 393-414
6. Djaldetti R, Melamed E. Management of response fluctuations: practical guidelines. Neurology 1998; 51: S36-40
7. Colosimo C, De Michele M. Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 1999; 6:1-21
8. Gorell JM, Rybicki BA, Johnson CC, et al. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999; 52: 115-9
9. Liou HH, Tsai MC, Chen CJ, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997; 48: 1583-8
10. Tzourio C, Rocca WA, Breteler MM, et al. Smoking and Parkinson's disease: an age-dependent risk effect? Neurology 1997; 49: 1267-72
11. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000: 283: 2674-9
12. Kuhn W, Winkel R, Woitalla D, et al. High prevalence of parkinsonism after occupational exposure to lead- sulfate batteries. Neurology 1998: 50: 1885-6
13. Gorell JM, Rybicki BA, Cole Johnson C, et al. Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology 1999; 18: 303-8
14. Kim Y, Kim JM, Kim JW, et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean? Mov Disord 2002; 17: 568-75
15. Choi IS. Parkinsonism after carbon monoxide poisoning. Eur Neurol 2002; 48: 30-3
16. Gorell JM, Johnson CC, Rybicki BA, et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998; 50: 1346-50
17. Marder K, Logroscino G, Alfaro B, et al. Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology 1998; 50: 279-81
18. Elbaz A, Grigoletto F, Baldereschi M. et al. Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. Europarkinson Study Group. Neurology 1999; 52: 1876-82
19. Gouider-Khouja N, Belal S, Hamida MB, et al. Clinical and genetic study of familial Parkinson's disease in Tunisia. Neurology 2000; 54: 1603-9
20. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999; 281: 341-6
21. Richter G, Sonnenschein A, Grunewald T, et al. Novel mitochondrial DNA mutations in Parkinson's disease. J Neural Transm 2002; 109: 721-9
22. de-Rijk MC. Launer L.J, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S21-3
23. Errea JM, Ara JR, Aibar C, et al. Prevalence of Parkinson's disease in Lower Aragon, Spain. Mov Disord 1999; 14: 596-604
24. Chio A, Magnani C, Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 1998; 13: 400-5
25. Melcon MO, Anderson DW, Vergara RH, et al. Prevalence of Parkinson's disease in Junin, Buenos Aires Province. Argentina. Mov Disord 1997; 12: 197-205
26. Kuopio AM, Marttila RJ, Helenius H, et al. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 1999; 52: 302-8
27. Wermuth L, Joensen P. Bunger N, et al. High prevalence of Parkinson's disease in the Faroe Islands. Neurology 1997; 49: 426-32
28. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999; 52: 1214-20
29. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. Br Med J 2000; 321: 21-2
30. Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844-9
31. Siderowf AD, Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Mov Disord 2000; 15: 439-45
32. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's disease: an estimation based on a 3- month prospective analysis. Pharmacoeconomics 1998; 14: 299-312
33. Dodel RC, Eggert KM, Singer MS, et al. Costs of drug treatment in Parkinson's disease. Mov Disord 1998; 13: 249-54
34. LeP-en C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16: 59-69
35. Kurlan R, Clark S, Shoulson I, et al. Economic impact of protective therapy for early Parkinson's disease [abstract]. Ann Neurol 1988; 24: 153
36. Conley SC, Kirchner JT. Medical and surgical treatment of Parkinson's disease: strategies to slow symptom progression and improve quality of life. Postgrad Med 1999; 106: 41-52
37. Koller WC. Levodopa in the treatment of Parkinson's disease. Neurology 2000; 55 Suppl. 4: S2-7
38. Nutt JG. Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985; 18: 537-43
39. COMTAN (entacapone tablets). European package leaflet. Novartis Pharmaceuticals, Horsham, UK
40. Kurth MC, Adler CH. COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology 1998; 50: 3-14
41. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000; 23: S109-15
42. COMTAN (entacapone tablets). US package insert. Novartis Pharmaceuticals, East Hanover (NJ); 2002
43. TASMAR (tolcapone tablets). US Package Insert. Roche Laboratories Inc., Nutley. NJ; 2002:
44. Olanow CW, and the TASMAR Advisory Panel. Tolcapone and hepatotoxic effects. Arch Neurol 2000; 57: 262-7
45. The European Agency for the Evaluation of Medicinal Products. Recommend ation for the renewal of the suspension of the marketing authorisation for TASMAR (tolcapone) - EU/1/97/044/001-006 [media release]. 2001
46. Myllyla VV, Sotaniemi KA, Illi A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 1993; 45 (5): 419-23
47. Stern MB. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview. Neurology 1997; 49: 2-9
48. Hutton JT, Metman LV, Chase TN, et al. Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923: a double-blind placebo-controlled study. Mov Disord 2001; 16: 459-63
49. Nilsson D, Nyholm D, Aquilonius SM, et al. Duodenal levodopa infusion in Parkinson's disease - long term experience. Acta Neurol Scan 2001; 104: 343-8
50. Ahlskog JE. Medical treatment of later-stage motor problems of Parkinson disease. Mayo Clin Proc 1999; 74: 1239-54
51. Rascol O. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease? J Neural Transm Suppl 1999; 55: 33-45
52. Whone AL, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-Dopa [abstract]. Neurology 2002; 58 Suppl. 3: A82
53. Le W-D, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001; 18 (6): 389-96
54. Arle JE, Alterman RL. Surgical options in Parkinson's disease. Med Clin North Am 1999; 83: 483-98
55. Defer G-L, Widner H, Marie R-M. et al. Core Assessment Program for Surgical lnterventional Therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14: 572-84
56. Hallett M, Litvan I. Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. Neurology 1999; 53: 1910-21
57. Lang AE. Surgery for Parkinson disease: A critical evaluation of the state of the art. Arch Neurol 2000; 57: 1118-25
58. Heikkinen H, Nutt JG, LeWitt PA, et al. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Clin Neuropharmacol 2001: 24: 150-7
59. Heikkinen H, Saraheimo M, Antila S, et al. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man: a study using a stable isotope technique. Eur J Clin Pharmacol 2001; 56: 821-6
60. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309-14
61. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997; 42: 747-55
62. Poewe WH. Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002; 105 (4): 245-55
63. Sagar H, Brooks DJ, UK-Irish ESG. The UK-Irish double-blind study of entaca-'pone in Parkinson's disease [abstract]. Movement Dis 2000; 15: 135
64. Rinne UK, Larsen JP, Siden A, et al. Long-term efficacy of entacapone in parkinsonian patients with motor fluctuations up to 3.5 years [abstract]. Eur J Neurol 2000; 7: 17
65. Piccini P, Brooks DJ, Korpela K, et al. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 68: 589-94
66. Kaakkola S, Teräväinen H, Ahtila S, et al. Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 1995; 2: 341-7
67. Durif F, Devaux I, Pere JJ, et al. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 2001; 45: 111-8
68. Lee MS, Kim HS, Cho EK, et al. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 2002; 58: 564-7
69. Myllyla VV, Kultalahti ER, Haapaniemi H, et al. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001; 8: 53-60
70. Nuijten MJ, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 2001; 4: 316-28
71. Palmer CS, Nuijten MJC, Schmier JK, et al. The cost-effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics 2002; 20: 617-28
72. Linna M, Taimela E, Apajasalo M, et al. Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease. Expert Reviews Pharmacoeconomics Outcomes Research 2002; 2: 91-7
73. Schapira AHV, Obeso JA, Olanow CW. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Neurology 2000: 55 Suppl. 4: S65-8
74. Orion Pharma. Orion pharmaceutical research and development [online]. Available from URL: http://www.orion.fi [Accessed 2002 Jun 24]